摘要
目的:探究血清CD3^(+)、CD4^(+)、CD8^(+)T淋巴细胞水平与局部晚期食管癌同步放化疗疗效及预后的关系。方法:回顾性分析2021年6月—2023年6月于泉州市光前医院进行局部晚期食管癌同步放化疗治疗的118例食管癌患者的临床资料,根据治疗效果分为有效组(n=93)、无效组(n=25),比较两组治疗前后血清CD3^(+)、CD4^(+)、CD8^(+)T淋巴细胞水平,采用受试者操作特征(ROC)曲线分析血清CD3^(+)、CD4^(+)、CD8^(+)T淋巴细胞水平联合诊断疗效的价值。根据治疗后6个月是否出现不良事件将其分为预后良好组(n=85)、预后不良组(n=33),比较两组基线资料及血清CD3^(+)、CD4^(+)、CD8^(+)T淋巴细胞水平,分析血清CD3^(+)、CD4^(+)、CD8^(+)T淋巴细胞水平与预后的相关性。结果:治疗后,有效组血清CD3^(+)、CD4^(+)、CD8^(+)T淋巴细胞水平均高于无效组,差异有统计学意义(P<0.05)。血清CD3^(+)、CD4^(+)、CD8^(+)T淋巴细胞水平联合预测疗效的AUC为0.911,高于血清CD3^(+)、CD4^(+)、CD8^(+)T淋巴细胞水平单独预测的0.827、0.743、0.736。预后良好组血清CD3^(+)、CD4^(+)、CD8^(+)T淋巴细胞水平高于预后不良组,差异有统计学意义(P<0.05)。Spearman相关性分析结果显示,血清CD3^(+)、CD4^(+)、CD8^(+)T淋巴细胞水平均与局部晚期食管癌患者预后呈正相关(P<0.05)。结论:血清CD3^(+)、CD4^(+)、CD8^(+)T淋巴细胞水平可作为临床评估食管癌患者同步放化疗疗效的辅助指标,与其预后呈正相关性,可为临床评估疗效及预后提供可靠依据。
Objective:To explore the correlation between serum levels of CD3^(+),CD4^(+)and CD8^(+)T lymphocytes and the efficacy and prognosis of concurrent chemoradiotherapy for locally advanced esophageal cancer.Method:Clinical data of 118 patients with locally advanced esophageal cancer who received concurrent chemoradiotherapy in Quanzhou Guangqian Hospital from June 2021 to June 2023 were retrospectively analyzed.According to the treatment effect,they were divided into effective group(n=93)and ineffective group(n=25).Serum levels of CD3^(+),CD4^(+)and CD8^(+)T lymphocytes were compared between the two groups before and after treatment.The value of serum CD3^(+),CD4^(+),CD8^(+)T lymphocyte levels combined with diagnostic efficacy was analyzed by receiver operating characteristic(ROC)curve.They were divided into good prognosis group(n=85)and poor prognosis group(n=33)according to the occurrence of adverse events 6 months after treatment.Baseline data and serum levels of CD3^(+),CD4^(+)and CD8^(+)T lymphocytes of the good prognosis group and poor prognosis group were compared,and the correlation between serum levels of CD3^(+),CD4^(+)and CD8^(+)T lymphocytes and prognosis was analyzed.Result:After treatment,the serum levels of CD3^(+),CD4^(+)and CD8^(+)T lymphocytes in the effective group were higher than those in the ineffective group,and the differences were statistically significant(P<0.05).The AUC of serum CD3^(+),CD4^(+),and CD8^(+)T lymphocytes combined to predict the curative effect was 0.911,which was higher than 0.827,0.743,and 0.736 of serum CD3^(+),CD4^(+),and CD8^(+)T lymphocytes alone.Serum levels of CD3^(+),CD4^(+)and CD8^(+)T lymphocytes in the good prognosis group were higher than those in the poor prognosis group,and the differences were statistically significant(P<0.05).Spearman correlation analysis showed that serum CD3^(+),CD4^(+),CD8^(+)T lymphocyte levels were positively correlated with the prognosis of patients with locally advanced esophageal cancer(P<0.05).Conclusion:Serum CD3^(+),CD4^(+),CD8^(+)T
作者
苏淼毅
苏松毅
蒋才慧
林剑辉
黄世宝
潘清辉
梁德川
郑维奇
孙争强
SU Miaoyi;SU Songyi;JIANG Caihui;LIN Jianhui;HUANG Shibao;PAN Qinghui;LIANG Dechuan;ZHENG Weiqi;SUN Zhengqiang(Quanzhou Guangqian Hospital,Quanzhou 362000,China;不详)
出处
《中外医学研究》
2024年第7期58-62,共5页
CHINESE AND FOREIGN MEDICAL RESEARCH
基金
泉州市科技计划项目(2021N003S)。
关键词
T淋巴细胞
局部晚期食管癌
同步放化疗
Levels of T lymphocyte
Locally advanced esophageal cancer
Concurrent chemoradiotherapy
